Alembic Limited (ALEMBICLTD) AI Stock Analysis

• Market Cap: ₹26.22B
• Dividend Yield: 2.36%
• Average Volume (3M): 22.23K
• Price to Earnings (P/E): 8.1
• Beta (1Y): 1.46
• Revenue Growth: 16.53%
• EPS Growth: 4.37%
• Country: IN
• Employees: 285
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 5.00
• Shares Outstanding: 256,781,830
• 10 Day Avg. Volume: 15,327
• 30 Day Avg. Volume: 22,227
• PEG Ratio: 0.53
• Price to Book (P/B): 1.10
• Price to Sales (P/S): 11.55
• P/FCF Ratio: 71.97
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 74 Outperform
• Price Target: ₹113.00 ▲(10.38% Upside)

Alembic Limited's strong financial performance and attractive valuation are the primary drivers of its stock score. The company's robust revenue growth and profitability metrics, combined with a low P/E ratio and reasonable dividend yield, suggest a solid investment opportunity. However, mixed technical indicators and potential sustainability concerns regarding profit metrics slightly temper the overall outlook.

Positive Factors

Revenue Growth

The significant revenue growth indicates robust expansion in the specialty and generic drug market, enhancing market position and future earnings potential.

Balance Sheet Strength

A low debt-to-equity ratio signifies low leverage and financial risk, providing the company with greater financial stability and flexibility for future investments.

Gross Profit Margin

A strong gross profit margin reflects effective cost management, which supports sustainable profitability and competitive advantage in the market.

Negative Factors

Profit Margin Sustainability

The unusually high net profit margin suggests potential non-recurring gains, which may not be sustainable, affecting long-term profitability expectations.

Cash Flow Challenges

Low free cash flow relative to net income indicates potential cash flow challenges, which could impact the company's ability to reinvest and grow sustainably.

Profit Metrics Inflation

Inflated profit metrics due to non-recurring gains may misrepresent the company's true profitability, posing risks to investor expectations and valuation accuracy.

Alembic Limited Business Overview & Revenue Model

Company Description

Alembic Limited (ALEMBICLTD) is a diversified company engaged in the pharmaceutical and biotechnology sectors. Founded in India, the company operates primarily in the development, manufacturing, and marketing of a wide range of pharmaceutical products, including generics and active pharmaceutical ingredients (APIs). Alembic Limited is also involved in research and development initiatives aimed at innovating new drug formulations and therapies, catering to both domestic and international markets.

How the Company Makes Money

Alembic Limited generates revenue primarily through the sale of its pharmaceutical products, which include generic medications and APIs. The company engages in both direct sales and distribution partnerships to reach a broad customer base, including hospitals, pharmacies, and healthcare providers. Additionally, Alembic Limited benefits from licensing agreements and collaborations with other pharmaceutical companies for research and development projects, which can yield royalty income and shared profits. The company also focuses on expanding its market presence in global markets, which contributes to its revenue growth through exports and international sales.

Alembic Limited Financial Statement Overview

Summary

Alembic Limited demonstrates strong financial health with impressive revenue growth and profitability metrics. The balance sheet is solid, supported by low leverage and high equity. However, some profit metrics appear inflated, possibly due to non-recurring gains, which may affect sustainability. While improvements in cash flow are evident, further enhancements in cash conversion and management are necessary to support long-term growth.

Income Statement

Alembic Limited shows strong revenue growth with a 50.8% increase from 2024 to 2025, demonstrating robust expansion in the specialty and generic drug market. The gross profit margin is healthy at 68.8% for 2025, reflecting effective cost management. However, the net profit margin is unusually high at 140%, likely due to one-time gains or accounting adjustments, which could be an anomaly. The EBIT margin of 37.4% and EBITDA margin of 76% indicate strong core operational profitability.

Balance Sheet

The company maintains a strong balance sheet with a low debt-to-equity ratio of 0.006 in 2025, signifying low leverage and financial risk. The equity ratio stands robust at 93.4%, showing a strong capital structure. Return on Equity (ROE) is high at 13.3%, driven by substantial net income, but this figure may be inflated by non-recurring items. Overall, the balance sheet reflects financial stability, though the high net income may not be sustainable.

Cash Flow

The cash flow statement reveals a positive shift in free cash flow, from negative in 2024 to positive in 2025, indicating improved cash generation. The operating cash flow to net income ratio of 0.28 suggests moderate cash conversion efficiency. The free cash flow to net income ratio of 0.11 is low, hinting at potential cash flow challenges despite high net income figures. The company shows progress in cash flow management, but sustainability remains a concern.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.21B	2.22B	1.57B	1.18B	713.69M	678.37M
Gross Profit	1.52B	1.53B	872.46M	702.07M	404.50M	392.74M
EBITDA	1.69B	1.69B	1.12B	939.86M	1.03B	213.43M
Net Income	3.17B	3.11B	2.69B	1.91B	2.22B	3.43B
Balance Sheet
Total Assets	0.00	25.03B	23.29B	22.05B	26.32B	24.09B
Cash, Cash Equivalents and Short-Term Investments	582.70M	582.80M	129.05M	464.09M	270.77M	225.14M
Total Debt	0.00	144.50M	91.49M	0.00	0.00	2.77M
Total Liabilities	-23.39B	1.64B	1.43B	1.27B	1.35B	1.12B
Stockholders Equity	23.39B	23.39B	21.86B	20.78B	24.97B	22.97B
Cash Flow
Free Cash Flow	0.00	356.00M	-336.03M	130.35M	-535.60M	-496.37M
Operating Cash Flow	0.00	863.70M	226.87M	388.52M	-177.47M	-21.82M
Investing Cash Flow	0.00	-265.80M	258.36M	72.96M	188.48M	-348.69M
Financing Cash Flow	0.00	-583.40M	-481.94M	-463.88M	-58.16M	-153.62M

Alembic Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 102.37
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ALEMBICLTD, the sentiment is Positive. The current price of 102.37 is above the 20-day moving average (MA) of 100.13, above the 50-day MA of 100.18, and below the 200-day MA of 103.94, indicating a neutral trend. The MACD of 0.26 indicates Negative momentum. The RSI at 54.31 is Neutral, neither overbought nor oversold. The STOCH value of 69.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ALEMBICLTD.

Alembic Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALEMBICLTD	74 Outperform	₹26.22B	8.09	―	2.36%	16.53%	4.37%
AUROPHARMA	74 Outperform	₹684.30B	19.99	―	0.34%	7.33%	-3.79%
IPCALAB	74 Outperform	₹362.90B	43.64	―	0.29%	9.66%	25.79%
ALKEM	72 Outperform	₹676.82B	28.67	―	0.80%	9.32%	11.25%
APLLTD	60 Neutral	₹166.32B	26.22	―	1.30%	11.42%	-1.91%
GLENMARK	53 Neutral	₹554.82B	54.94	―	0.26%	30.27%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Alembic Limited Corporate Events

Alembic Limited Opens Special Window for Share Transfer Re-lodgement

Alembic Limited has announced a special window for the re-lodgement of transfer requests for physical shares. This initiative, in response to a SEBI circular, allows investors with previously rejected or returned transfer deeds lodged before April 1, 2019, to resubmit them for transfer in demat mode. The window is open from July 1, 2025, to January 6, 2026, providing an opportunity for eligible investors to rectify past deficiencies and complete their share transfers.